Longer duration of thalidomide monotherapy results in improved outcome in relapsed/refractory multiple myeloma

被引：2
|
作者：
von Liliefifeld-Toal, Marie [1 ]
Hahn-Ast, Corinna [1 ]
Bertolini, Francesco
Bila, Jelena
Boulin, Mathieu
Oakervee, Heather
Cibeira, Teresa
Cook, Gordon
Dmoszynska, Anna
Fenk, Roland
Guglielmelli, Tommasina
Goldschmidt, Hartmut
Hattori, Yukata
Myers, Bethan
Offidani, Massimo
Patriarca, Francesca
Petrucci, Maria Teresa
Pini, Massimo
Prince, Miles
Schey, Steve
Sonneveld, Pieter
Yakoub-Agha, Ibrahim
Waage, Anders
Glasmacher, Axel [1 ]
机构：
[1] Univ Bonn, D-5300 Bonn, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2725.2725
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2725
引用
收藏
页码：800A / 800A
页数：1
相关论文
共 50 条
  • [21] Thalidomide plus melphalan in relapsed-refractory multiple myeloma.
    Offidani, M
    Mele, A
    Marconi, M
    Corvatta, L
    Candela, M
    Pieroni, S
    Malerba, L
    Rupoli, S
    Olivieri, A
    Leoni, P
    BLOOD, 2001, 98 (11) : 311B - 311B
  • [22] Thalidomide in relapsed or refractory multiple myeloma: How much and for how long?
    Abdalla, SH
    Mahmoud, S
    LEUKEMIA & LYMPHOMA, 2003, 44 (06) : 989 - 991
  • [23] Efficacy of thalidomide monotherapy in relapsed or refractory patients with multiple myeloma: A systematic review of the 42 clinical trials and 1629 patients
    Glasmacher, A
    Hahn, C
    Hoffmann, F
    Naumann, R
    Goldschmidt, H
    Von Lilienfeld-Toal, M
    Schmidt-Wolf, I
    Gorschlueter, M
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 24 - 24
  • [24] Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
    Kropff, Martin
    Baylon, Honorata Giongco
    Hillengass, Jens
    Robak, Tadeusz
    Hajek, Roman
    Liebisch, Peter
    Goranov, Stefan
    Hulin, Cyrille
    Blade, Joan
    Caravita, Tommaso
    Avet-Loiseau, Herve
    Moehler, Thomas M.
    Pattou, Claire
    Lucy, Lela
    Kueenburg, Elisabeth
    Glasmacher, Axel
    Zerbib, Robert
    Facon, Thierry
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2012, 97 (05): : 784 - 791
  • [25] Thalidomide in the treatment of relapsed and refractory myeloma.
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Witzig, TE
    Lust, JA
    Kyle, RA
    Gertz, MA
    Greipp, PR
    BLOOD, 1999, 94 (10) : 316A - 316A
  • [26] Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Vij, Ravi
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Facon, Thierry
    Pegourie, Brigitte
    Benboubker, Lotfi
    Gasparetto, Cristina
    Amiot, Martine
    Moreau, Philippe
    Diehl, Susan
    Alzate, Stefanie
    Ross, Jeremy A.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh K.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
    Dimopoulos, Meletios
    Bringhen, Sara
    Anttila, Pekka
    Capra, Marcelo
    Cavo, Michele
    Cole, Craig
    Gasparetto, Cristina
    Hungria, Vania
    Jenner, Matthew
    Vorobyev, Vladimir
    Ruiz, Eduardo Yanez
    Yin, Jian Y.
    Saleem, Rao
    Hellet, Maeva
    Mace, Sandrine
    Paiva, Bruno
    Vij, Ravi
    BLOOD, 2021, 137 (09) : 1154 - 1165
  • [28] PHASE 1 STUDY OF VENETOCLAX MONOTHERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Kumar, S.
    Vij, R.
    Kaufman, J. L.
    Mikhael, J.
    Facon, T.
    Pegourie, B.
    Benboubker, L.
    Gasparetto, C.
    Amiot, M.
    Moreau, P.
    Diehl, S.
    Alzate, S.
    Ross, J.
    Dunbar, M.
    Zhu, M.
    Agarwal, S.
    Leverson, J.
    Maciag, P.
    Verdugo, M.
    Touzeau, C.
    HAEMATOLOGICA, 2016, 101 : 328 - 328
  • [29] Thalidomide in the treatment of relapsed multiple myeloma
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Lust, JA
    Witzig, TE
    Kyle, RA
    Gertz, MA
    Greipp, PR
    MAYO CLINIC PROCEEDINGS, 2000, 75 (09) : 897 - 901
  • [30] Factors predictive of outcome in relapsed, refractory multiple myeloma patients treated with bortezomib, melphalan, prednisone, and thalidomide (VMPT)
    Palumbo, A. P.
    Ambrosini, M. T.
    Benevolo, G.
    Pescosta, N.
    Callea, V.
    Cangialosi, C.
    Caravita, T.
    Morabito, F.
    Gay, F.
    Boccadoro, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345